Nasdaq GlobeNewswire

SNOMED International Welcomes Cyprus to a Thriving, Global Community of Practice

Del

London, United Kingdom, Sept. 06, 2018 (GLOBE NEWSWIRE) -- The Cyprus Ministry of Health and SNOMED International jointly announce the addition of Cyprus as the organization’s thirty-fourth Member.


With a developing e-health program across the country’s hospital and health center landscape, Cyprus joins SNOMED International to bring structure and consistency in the sharing of health information for patient care, clinical decision support and research purposes. Within the European region, the promise of cross-border care mobility is believed to be the single most important revolution in healthcare. Preserving the sanctity of patient information through structured data becomes critical to this vision.

SNOMED CT is the world’s most comprehensive and precise health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. “SNOMED CT is a core element in building a platform for accurate clinical information exchange and data analysis and SNOMED International applauds Cyprus’s commitment to this vision” states SNOMED International’s CEO, Don Sweete. “With the increasing need to support cross-border health, SNOMED CT is positioned as the best available core reference terminology for cross-border, national and regional eHealth deployments in Europe.”

In recent years, Cyprus is dynamically entering the eHealth era. Codification is an essential part of this journey as health information should be captured, monitored, analyzed and disseminated among health professionals, health policy makers, and the public. Taking part in the European ‘eHealth Network’ project to establish cross border health care, of which the dominant terminology used is SNOMED CT, further supports the need for codification. Through this project, Cyprus has seen this as an opportunity to expand our codification horizons. For this reason, we joined SNOMED CT as a member country, in order to be able to promote health information coding, in a unifying way, among different local health software. The aim of which is to better guide our understanding and comparability of existing health information data.

Vasos Scoutellas, Coordinator of the Health Monitoring Unit of the Ministry of Health recognizes the value of membership in SNOMED International for Cyprus. “At the Health Monitoring Unit of the Ministry of Health of Cyprus, myself, as the coordinator, and my colleagues, fully endorse the promotion, adoption and deployment of SNOMED CT in the health system of Cyprus. With its use, as a country, we will have a uniform way of documenting health issues. This will help us to have better and comparable statistics within the country.”

Cyprus becomes the 21st Member in the European, Middle East and African region to join SNOMED International, setting the expectation for increased interoperability as well as the promise of leveraging learnings amongst its regional and international counterparts. SNOMED CT becomes part of the Cyprus national infrastructure to ensure the exchange of accurate, relevant and timely information across all the information systems to support direct care, self-care and secondary uses of health information.

To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.


About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Visit the SNOMED International website to learn more.

About the Cyprus Ministry of Health

The mission of the Ministry of Health is the continuous improvement of the health of the population of Cyprus, through the prevention of disease, and the provision to every citizen of high level health care, respecting the rights of every patient to high quality medical care delivered with dignity.  Health information technology exists in two public hospitals (out of seven) and in in few health centers. Over the subsequent five years, Cyprus will implement a new health information system across all public hospitals and health centers.

The Health Monitoring Unit of the Ministry of Health is responsible with providing its society with necessary and useful information, as well as high quality knowledge of public health issues. We have developed and maintained national registries on births, deaths, cancer, HIV/AIDS and public hospital discharge summaries. In addition, we are responsible for the implementation of health information codification in Cyprus. In this context, we will promote and support the adoption and deployment of SNOMED CT among all health professionals.  

Visit the Ministry of Health of Cyprus, Health Monitoring Unit to learn more.

Attachment

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Gratomic Announces Non-Brokered Private Placement16.11.2018 14:00Pressemelding

TORONTO, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 10,000,000 working capital units (the “WC Unit”) for up to $1,000,000 (the “Offering”). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant (“WC Warrant”). Each WC Warrant entitles the holder to purchase one (1) common share (a “WC Warrant Share”) at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the “Final Trading Day”) is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of

BlissCo Receives Cannabis Sales License from Health Canada16.11.2018 14:00Pressemelding

Not for distribution in the U.S. or to U.S. Newswires VANCOUVER, British Columbia, Nov. 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) (“BlissCo” or the “Company”), is pleased to announce that it has received a comprehensive sales license from Health Canada to sell bulk cannabis and pre-packaged, labeled, and tested cannabis products. “We are thrilled to receive our sales license and to be able to start pre-registering clients and supplying both the robust medical and adult-use markets in Canada with our premium cannabis products,” said Damian Kettlewell, CEO of BlissCo. “BlissCo is committed to providing top-tier service to all of our customers.” The Company will soon be launching its e-commerce website and BlissConnect, a telemedicine app for medical cannabis consultations, to service its medical clients. The Company is currently ready to pre-register clients wishing to be first in line when shipping begins. To pre-registe

Mitratech Listed Among Financial Times’ Inaugural Top 35 Intelligent Business Award Winners and Other Prestigious Categories16.11.2018 10:00Pressemelding

Legal Tech Top 10 FTIL Intelligent Business Award for Contracting FTIL Intelligent Business Award for Use of Legal Technology AUSTIN, Texas, Nov. 16, 2018 (GLOBE NEWSWIRE) -- The Financial Times’ inaugural FT Intelligent Business Special Report has recognized Mitratech among the top companies with the greatest impact on the practice and business of law. The report highlights the integration of people, processes, and data to solve a legal business’ operational challenges and how the ramifications of this back-office revolution are felt across organizations everywhere. “The fact that the Financial Times is now tracking the impact of legal technology reinforces that the industry is at a tipping point,” said Jason Parkman, Mitratech CEO. “There’s more transformation that lies ahead. We are honored and humbled to be a part of that movement and in good company with several clients we were recognized with.” The company was presented with the following honors: FT Intelligent Business Top 35: M

GridGain Ranked 77th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™16.11.2018 09:00Pressemelding

1,724 Percent Growth Over the Past Four Years Ranks 19th in the San Francisco Bay Area FOSTER CITY, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, is ranked No. 77 on the Deloitte 2018 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. GridGain, which grew 1,724 percent over the past four years, was the 19th fastest growing company in the San Francisco Bay Area. “GridGain continues to benefit from strong market demand for our market-leading in-memory computing platform that helps customers realize their digital transformation and omnichannel customer experience initiatives,” said Abe Kleinfeld, President and CEO of GridGain Systems. “When you combine the best talent in the industry with great execution and strong customer demand, wonderful things happen.” “Congratulations to the Deloit

Bombardier Will Fully Cooperate with the AMF Review16.11.2018 00:06Pressemelding

MONTRÉAL, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Bombardier acknowledges the announcement by the Autorité des marchés financiers (AMF) that it is reviewing the operations surrounding the establishment by Bombardier of an Automatic Securities Disposition Plan (ASDP) in August 2018 and various subsequent announcements. The ASDP had been reviewed by the AMF prior to its establishment on August 15, 2018. Bombardier intends to fully cooperate with the AMF in its review. The Company has taken the necessary measures to suspend all sales of securities pursuant to the ASDP until further notice. About Bombardier With over 69,500 employees across four business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montreal, Canada, Bombardier has product

ERYTECH Partners with New York Blood Center for Red Blood Cell Supply and Research15.11.2018 22:05Pressemelding

LYON, France and CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced a strategic partnership with New York Blood Center (NYBC) for red blood cell supply and research. The partnership encompasses NYBC becoming a long-term supplier of donor red blood cells (RBC) to ERYTECH, enabling ERYTECH to diversify and broaden its supply of RBC source materials for the production of eryaspase and future product candidates derived from its proprietary ERYCAPS® platform as the company ramps up clinical development. Specifically for the Phase 3 trial in second-line metastatic pancreatic cancer that recently started enrolling patients in Europe, and the Phase 2 trial in first-line triple negative breast cancer (TNBC), which are both expected to begin enrollment in the United States early in 2019. The partnershi

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom